Hereditary antithrombin III deficiency: Case report and review of recent therapeutic advances
article
OA: closed
CC0
⤵ 2 in-corpus citations
AI-generated summary
This case report details a family with hereditary antithrombin III deficiency, presenting a patient successfully treated with streptokinase, antithrombin III concentrate, and danazol for thromboembolic complications.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
We report on a newly diagnosed family with hereditary antithrombin III deficiency, with thromboembolic complications in the propositus. Both the propositus and his asymptomatic sister had decreased plasma levels of antithrombin III antigen and activity (28-52% of normal with good agreement between functional and immunologic assays). The propositus developed deep venous thrombosis, followed by massive pulmonary emboli despite heparin therapy and was treated with streptokinase and heparin with excellent results. Shortly thereafter, small bowel obstruction required surgical intervention, and antithrombin III concentrate, recently available in the United States as an investigational new drug (I.N.D.), was administered with no postoperative thrombotic complications. He was subsequently asymptomatic while on warfarin prophylaxis but twice developed venous thrombosis when he failed to take warfarin. The addition of danazol therapy led to a sustained rise in the antithrombin III level. Each of these therapeutic approaches is discussed and the literature reviewed with emphasis on the newer agents--streptokinase, antithrombin III concentrate, and danazol.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (2)
References (38)
- doi:10.1055/s-0038-1650046 via openalex
- doi:10.1159/000299612 via openalex
- doi:10.1080/22953337.1982.11718833 via openalex
- doi:10.1111/j.1365-2141.1982.00479.x-i1 via openalex
- doi:10.1055/s-0038-1654228 via openalex
- doi:10.1002/ajh.2830010310 via openalex
- doi:10.1111/j.1365-2141.1982.tb01949.x via openalex
- doi:10.1159/000299460 via openalex
- W2264524581 via openalex
- W2278402360 via openalex
- W2413962587 via openalex
- W2464863036 via openalex
- W6694859833 via openalex
- W6719486162 via openalex
- doi:10.1159/000214687 via openalex
- doi:10.1097/00000658-197506000-00004 via openalex
- doi:10.1002/ajh.2830020404 via openalex
- doi:10.1016/s0140-6736(78)90196-4 via openalex
- doi:10.1055/s-0038-1647677 via openalex
- doi:10.1111/j.1365-2141.1982.tb03858.x via openalex
- doi:10.1111/j.1600-0609.1981.tb01369.x via openalex
- doi:10.1056/nejm198010093031502 via openalex
- doi:10.1136/jcp.26.7.532 via openalex
- doi:10.1159/000182013 via openalex
- doi:10.1016/0049-3848(79)90224-x via openalex
- doi:10.1055/s-0038-1650020 via openalex
- doi:10.1055/s-0038-1656297 via openalex
- doi:10.1016/0049-3848(81)90304-2 via openalex
- doi:10.1093/oxfordjournals.qjmed.a067730 via openalex
- doi:10.1016/0049-3848(81)90027-x via openalex
- doi:10.1016/s0308-2261(21)00229-0 via openalex
- doi:10.1111/j.0954-6820.1978.tb08478.x via openalex
- doi:10.1016/s0140-6736(77)91429-5 via openalex
- doi:10.1016/s0140-6736(83)90618-9 via openalex
- doi:10.1182/blood.v43.2.219.219 via openalex
- doi:10.1111/j.1600-0609.1980.tb02352.x via openalex
- doi:10.1097/00005792-198307000-00002 via openalex
- doi:10.1016/0049-3848(77)90208-0 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-05-10T11:01:14.481557+00:00
- unpaywall
- last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0
· commercial use OK